<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00544414</url>
  </required_header>
  <id_info>
    <org_study_id>98147</org_study_id>
    <secondary_id>P30CA033572</secondary_id>
    <secondary_id>CHNMC-98147</secondary_id>
    <secondary_id>CDR0000566884</secondary_id>
    <nct_id>NCT00544414</nct_id>
  </id_info>
  <brief_title>Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer</brief_title>
  <official_title>Multimodality Management of Head and Neck Cancer: A Phase II Trial of Induction Chemotherapy, Organ Preservation Surgery, and Concurrent Chemoradiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor&#xD;
      cells, either by killing the cells or by stopping them from dividing. Giving combination&#xD;
      chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue&#xD;
      that needs to be removed. Radiation therapy uses high-energy x-rays to kill tumor cells.&#xD;
      Drugs such as gemcitabine and cisplatin may make tumor cells more sensitive to radiation&#xD;
      therapy. Giving combination chemotherapy before surgery or radiation therapy may kill more&#xD;
      tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving chemotherapy followed by surgery,&#xD;
      chemotherapy, and radiation therapy works in treating patients with locally advanced head and&#xD;
      neck cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To assess the complete and overall response rate of neoadjuvant docetaxel, cisplatin,&#xD;
           fluorouracil, and leucovorin calcium in previously untreated patients with local&#xD;
           regionally advanced head and neck cancer.&#xD;
&#xD;
        -  To evaluate the feasibility of a multimodality treatment approach with the goal of&#xD;
           reducing long-term sequelae.&#xD;
&#xD;
        -  To evaluate prospectively, the impact of neoadjuvant chemotherapy, concurrent&#xD;
           chemoradiotherapy, and organ preservation surgery on overall survival, time to&#xD;
           progression, and pattern of disease recurrence in these patients.&#xD;
&#xD;
        -  To evaluate prospectively, biochemical correlates of response and prognosis, including&#xD;
           markers such as thymidylate synthetase, ribonucleotide reductase, and ERCC1 (measured by&#xD;
           quantitative PCR), p53 (evaluated by IHC), and HPV status and apoptosis (TUNEL assay).&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To evaluate treatment-associated morbidity with the use of a quality of life assessment&#xD;
           tool.&#xD;
&#xD;
        -  To compare the results of diagnostic salivary cytology with those of histopathology at&#xD;
           initial diagnosis as well as follow-up in head and neck cancer patients.&#xD;
&#xD;
        -  To evaluate the tolerability of combined chemoradiotherapy using gemcitabine and&#xD;
           cisplatin after definitive surgery for squamous cell carcinoma of the head and neck.&#xD;
&#xD;
      OUTLINE: Patients receive neoadjuvant induction chemotherapy comprising docetaxel IV over 1&#xD;
      hour on day 1 and cisplatin IV, leucovorin IV, and fluorouracil IV over 24 hours on days 1-4.&#xD;
      Induction chemotherapy repeats every 28 days for 3 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Patients with partial response at the primary site may undergo radical or functional&#xD;
      resection of the primary tumor within 3 weeks of completion of neoadjuvant therapy.&#xD;
&#xD;
      Beginning within 4 weeks of completion of neoadjuvant therapy, patients with persistent&#xD;
      disease or complete response after chemotherapy at the primary or neck then undergo&#xD;
      radiotherapy 5 days a week for 7 weeks and receive gemcitabine hydrochloride IV over 30&#xD;
      minutes and cisplatin IV over 60 minutes on day 1 of each week of radiotherapy in the absence&#xD;
      of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients complete the FACT-H&amp;N quality of life questionnaire at baseline and at completion of&#xD;
      neoadjuvant therapy.&#xD;
&#xD;
      Tissue biopsies are collected at baseline, periodically during therapy, at surgery, and after&#xD;
      radiotherapy. Tissue is examined for gene and protein expression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 7, 2000</start_date>
  <completion_date type="Anticipated">December 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 25, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete and overall response rate</measure>
    <time_frame>30 days after last course of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility</measure>
    <time_frame>30 days after last course of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Prospective impact of neoadjuvant chemotherapy, concurrent chemoradiotherapy, and organ preservation surgery on overall survival, time to progression, and pattern of disease recurrence</measure>
    <time_frame>30 days after last course of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Biochemical correlates</measure>
    <time_frame>30 days after last course of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-associated morbidity</measure>
    <time_frame>30 days after last course of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of diagnostic salivary cytology with histopathology at initial diagnosis and at follow-up</measure>
    <time_frame>30 days after last course of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>30 days after last course of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive neoadjuvant induction chemotherapy comprising docetaxel IV over 1 hour on day 1 and cisplatin IV, leucovorin IV, and fluorouracil IV over 24 hours on days 1-4. Induction chemotherapy repeats every 28 days for 3 courses.&#xD;
Patients with partial response at the primary site may undergo radical or functional resection of the primary tumor within 3 weeks of completion of neoadjuvant therapy.&#xD;
Beginning within 4 weeks of completion of neoadjuvant therapy, patients with persistent disease or complete response after chemotherapy at the primary or neck then undergo radiotherapy 5 days a week for 7 weeks and receive gemcitabine hydrochloride IV over 30 minutes and cisplatin IV over 60 minutes on day 1 of each week of radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed squamous cell carcinoma of the head and neck, including any&#xD;
             of the following subtypes:&#xD;
&#xD;
               -  Oral cavity&#xD;
&#xD;
               -  Oropharynx&#xD;
&#xD;
               -  Hypopharynx&#xD;
&#xD;
               -  Larynx&#xD;
&#xD;
          -  Stage III or IV disease&#xD;
&#xD;
               -  Stage II carcinoma of the larynx, hypopharynx, or base of tongue allowed&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Resectable disease, defined as tumors that are potentially curable by surgery and&#xD;
             radiotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status ≥ 60%&#xD;
&#xD;
          -  ANC ≥ 1,500/μL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/μL&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL OR creatinine clearance &gt; 60 mL/min&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  Transaminases and alkaline phosphatase meeting 1 of the following criteria:&#xD;
&#xD;
               -  ALT or AST ≤ 2.5 times upper limit of normal (ULN) AND alkaline phosphatase&#xD;
                  normal&#xD;
&#xD;
               -  Alkaline phosphatase ≤ 4 times ULN AND ALT and AST normal&#xD;
&#xD;
               -  ALT or AST &lt; 1.5 times ULN AND alkaline phosphatase &lt; 2.5 times ULN&#xD;
&#xD;
          -  Free of serious infection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior malignancy allowed for purposes of determining disease-free or overall&#xD;
             survival except adequately treated basal cell or squamous cell skin cancer, in situ&#xD;
             cervical cancer, or other cancer for which the patient has been disease free for 5&#xD;
             years&#xD;
&#xD;
          -  No unstable angina, history of congestive heart failure, or acute myocardial&#xD;
             infarction within the past 6 months&#xD;
&#xD;
          -  No current symptomatic, neurosensory or neuromotor toxicity ≥ grade 2&#xD;
&#xD;
          -  No other significant medical or psychiatric condition incompatible with the protocol&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy or radiotherapy for head and neck cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen I. Shibata, MD</last_name>
    <role>Study Chair</role>
    <affiliation>City of Hope Comprehensive Cancer Center</affiliation>
  </overall_official>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 13, 2007</study_first_submitted>
  <study_first_submitted_qc>October 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2007</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage II squamous cell carcinoma of the larynx</keyword>
  <keyword>stage II squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the oropharynx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

